Related Experiment Video
Updated: Mar 13, 2026
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.5K
Summary
Ceritinib offers an effective second-line treatment for ALK-positive non-small cell lung cancer, improving progression-free survival by 4 months compared to chemotherapy in patients resistant to crizotinib.
Area of Science:
- Oncology
- Pharmacology
Background:
- Crizotinib resistance is a challenge in ALK-positive non-small cell lung cancer (NSCLC).
- Ceritinib is utilized as a second-line therapy in this patient population.
Purpose of the Study:
- To evaluate the efficacy of ceritinib versus chemotherapy as a second-line treatment for ALK-positive NSCLC.
Main Methods:
- A randomized trial comparing ceritinib to chemotherapy was conducted.
- Progression-free survival was the primary endpoint assessed.
Main Results:
- Ceritinib demonstrated a 4-month increase in progression-free survival compared to chemotherapy.
- This finding was presented at the European Society for Medical Oncology 2016 Congress.
Conclusions:
- Ceritinib is confirmed as an effective second-line treatment option for ALK-positive NSCLC patients with crizotinib resistance.
Related Concept Videos
02:56Treatment Resistent Cancers
1.4K
1.4K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:57Targeted Cancer Therapies
1.7K
1.7K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K